Tickers

1. Composite Trajectory Verdict

The income statement carries the most weight for assessing LQDA's trajectory because the company transitioned from pre-revenue to commercial-stage in mid-2025, making revenue ramp, profitability inflection, and expense scaling the primary drivers of value; cash flow and balance sheet trends are critical secondary validators given the HCR debt covenants and litigation overhang.

Composite Trajectory: Improving

All three financial statements show clear improvement. The income statement swung from a $128.3M net loss in FY2024 to a $68.9M net loss in FY2025 and then to a $127.6M net income in the first half of 2026 (10-K 2025-12-31, Consolidated Statements of Operations; 10-Q 2026-06-30, Condensed Consolidated Statements of Operations). Cash flow from operations improved from -$93.4M in FY2024 to -$35.7M in FY2025 and turned strongly positive at +$133.2M in H1 2026 (10-K 2025-12-31, Consolidated Statements of Cash Flows; 10-Q 2026-06-30, Condensed Consolidated Statements of Cash Flows). The balance sheet strengthened with cash rising from $176.5M at FY2024 to $190.7M at FY2025 to $284.2M at June 2026, while stockholders’ equity recovered from $44.7M to $195.1M over the same span (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Condensed Consolidated Balance Sheets). No statement shows a deteriorating trend.

2. Red Flags

• High fixed debt service with cash covenant: The HCR Agreement requires quarterly payments (H1 2026: $28.0M; FY2025: $21.0M) and a $15.0M minimum cash covenant through 2033 (10-Q 2026-06-30, Note 11; 10-K 2025-12-31, Liquidity and Capital Resources).
• Large and growing gross-to-net accruals: Accrued GTN deductions rose to $74.4M at June 2026 from $35.5M at December 2025, representing significant estimation risk on $300.3M H1 2026 product sales (10-Q 2026-06-30, Note 7).
• Declining service revenue stream: Service revenue fell 28% YoY in FY2025 ($10.0M vs $14.0M) and 21% YoY in H1 2026 ($4.3M vs $5.4M) due to CADD‑MS 3 pump constraints (10-K 2025-12-31, MD&A; 10-Q 2026-06-30, MD&A).
• Multiple patent litigations seeking injunctions: United Therapeutics has filed four separate suits ('327, '782, '494, trade secret, breach of contract) seeking to remove YUTREPIA from the market (10-Q 2026-06-30, Note 14).
• Non-cash interest expense consuming earnings: Interest expense (non‑cash accretion) was $24.2M in FY2025 and $12.8M in H1 2026, exceeding operating income in FY2025 (10-K 2025-12-31, Consolidated Statements of Operations; 10-Q 2026-06-30, Condensed Consolidated Statements of Operations).
• Accumulated deficit remains substantial: $498.7M at June 2026 despite recent profitability (10-Q 2026-06-30, Condensed Consolidated Balance Sheets).

3. Earnings Assessment (Income Statement)

Earnings Trajectory: Improving

Revenue jumped from $14.0M in FY2024 to $158.3M in FY2025 (1031% increase) driven by $148.3M of YUTREPIA product sales launched in June 2025 (10-K 2025-12-31, Consolidated Statements of Operations). H1 2026 revenue reached $304.5M vs $12.0M in H1 2025, with product sales of $300.3M vs $6.5M (10-Q 2026-06-30, Condensed Consolidated Statements of Operations). Net loss narrowed from -$128.3M (FY2024) to -$68.9M (FY2025) and reversed to +$127.6M net income in H1 2026 (10-K 2025-12-31, Consolidated Statements of Operations; 10-Q 2026-06-30, Condensed Consolidated Statements of Operations). Operating income followed the same pattern: -$121.3M → -$51.4M → +$147.0M. Product gross margin remained high (~93% in FY2025, ~93% in H1 2026). SG&A and R&D grew but were far outpaced by revenue.

4. Cash Generation Assessment (Statement of Cash Flows)

Cash Trajectory: Improving

Operating cash flow improved from -$93.4M (FY2024) to -$35.7M (FY2025) to +$133.2M (H1 2026) (10-K 2025-12-31, Consolidated Statements of Cash Flows; 10-Q 2026-06-30, Condensed Consolidated Statements of Cash Flows). The H1 2026 swing was driven by $216.1M higher net income adjusted for non‑cash items, partially offset by $12.8M unfavorable working capital changes (10-Q 2026-06-30, MD&A). Financing activities shifted from net inflows of $194.7M (FY2024) and $72.0M (H1 2025) to net outflows of -$24.7M (H1 2026) as the company repaid $28.0M on the HCR Agreement (10-K 2025-12-31, Consolidated Statements of Cash Flows; 10-Q 2026-06-30, Condensed Consolidated Statements of Cash Flows). Cash and equivalents grew from $176.5M (FY2024) to $190.7M (FY2025) to $284.2M (June 2026).

5. Balance Sheet Assessment

Balance Sheet Trajectory: Improving

Total assets grew from $230.3M (FY2024) to $327.9M (FY2025) to $521.9M (June 2026), led by cash ($176.5M → $190.7M → $284.2M), receivables ($2.7M → $54.1M → $108.6M), and inventory ($0.2M → $23.8M → $36.2M) (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Condensed Consolidated Balance Sheets). Total liabilities rose from $150.9M to $283.2M to $326.8M, but long-term debt (HCR) declined from $191.3M (FY2025) to $176.1M (June 2026) due to scheduled payments (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Note 11). Stockholders’ equity recovered from $44.7M (FY2025) to $195.1M (June 2026) as net income reduced the accumulated deficit from $626.3M to $498.7M (10-K 2025-12-31, Consolidated Balance Sheets; 10-Q 2026-06-30, Condensed Consolidated Balance Sheets). The minimum cash covenant ($15.0M) is comfortably met.

6. Data Gaps

• Quarterly standalone results for Q3 2025 and Q4 2025 (only annual FY2025 and H1 2025/H1 2026 are directly comparable).
• Full-year 2026 cash flow and balance sheet projections beyond H1.
• Detailed gross-to-net adjustment rollforward (only period-end balances disclosed).
• Breakdown of HCR Agreement payment allocation between principal and interest (only total payments shown).
• Outcome and timing of the multiple pending patent litigations (disclosed as unquantifiable).